BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2014 Earnings Results

Biocryst Pharmaceuticals Misses on EPS, Stock Down 13.8%

Biocryst Pharmaceuticals reported a loss that was slightly worse than expected, leading to a significant drop in stock price. The lack of revenue figures and forward guidance contributed to investor uncertainty, resulting in a 13.8% decline in the stock following the earnings release. This reaction indicates that investors are cautious about the company's short-term outlook.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.17	N/A	-4.29%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about the current market conditions impacting performance. They did not provide any forward-looking guidance.

Management did not provide specific revenue guidance for the upcoming quarters.

The company acknowledged challenges in meeting market expectations.

Biocryst Pharmaceuticals Misses on EPS, Stock Down 13.8%

Key numbers

Management commentary

BioCryst Pharmaceuticals, Inc.

More earnings this week

Biocryst Pharmaceuticals Misses on EPS, Stock Down 13.8%

Key numbers

Management commentary